Methodology
The Metabolic-Fit Score, explained
Every GLP-1 provider on this site is scored out of 100 on the same six weighted factors — chosen and weighted for mothers considering GLP-1 care postpartum, while managing PCOS or a history of gestational diabetes, or through the perimenopausal shift. A score is our editorial judgment, built from each provider's public disclosures and our review. Commissions don't change a provider's score. CoreAge Rx is a featured partner; providers we work with may appear first.
- 6
- weighted factors
- 100
- points possible
- 20%
- heaviest weight
- 349
- providers scored
The six factors
1. Postpartum & breastfeeding guidance
20%Whether the program is set up to talk through the timing that actually matters for mothers — GLP-1 medicines are not used in pregnancy, and semaglutide carries a two-month washout before a planned pregnancy. On breastfeeding, injectable semaglutide labels describe missing human-milk data; Zepbound and Mounjaro include a human milk-transfer study but no infant-outcome or milk-production data. These injectable labels call for breastfeeding benefits to be weighed against the mother's clinical need; every GLP-1 pill label (Wegovy tablets, Rybelsus, Foundayo) says breastfeeding is not recommended. We reward providers whose clinicians will raise that conversation, along with contraception and conception timing, rather than shipping a vial and moving on.
2. PCOS & hormonal fit
20%How well the approach fits a mother's hormonal metabolism — access to tirzepatide (often preferred where insulin resistance drives the weight), awareness of a gestational-diabetes history and the perimenopausal shift, and whether the program treats more than a number on the scale.
3. Clinical oversight & labs
20%Whether a licensed clinician — not just an intake form — stands behind the prescription, and whether the program runs or reviews labs. This matters more, not less, when thyroid, glucose and hormonal markers are already in motion after a pregnancy or into midlife.
4. True monthly cost
15%The real all-in monthly price, and whether it's honest: no teaser first-month rate that quietly triples at refill, no membership or consult fees stacked on top, no insurance-dependent number that only reveals itself after intake.
5. Ongoing support
15%The quality of continuing care through the sleep-deprived reality of early motherhood — side-effect and titration guidance, responsiveness, and whether support disappears once the first vial ships.
6. Cancellation fairness
10%How easily you can pause, switch or quit — and whether the provider locks you into contracts, forced auto-ships, or makes leaving deliberately painful when life with a baby changes your plans.
How we stay honest
- Partners, disclosed. CoreAge Rx is a featured partner; providers we work with may appear first. Affiliate relationships are disclosed site-wide, and commissions don't change a provider's score.
- Disclosed limits. The rubric is applied by Elena Voss, our metabolic-health editor, not a treating clinician. The evidence behind each score is checked against its cited primary sources, which are linked inline so you can audit any figure yourself. We claim no medical license we don't hold, and we don't claim a clinical reviewer we don't have.
- We name the limits. Most telehealth brands are general metabolic programs, not OB or hormone clinics. Where the postpartum or PCOS framing is broad rather than specialized, we say so and score it down.
- Facts are sourced, scores are judgment. Pricing, states served, and brand access reflect each provider's public disclosures at last review; medical claims are tied to primary research or FDA labeling; the weighted score is ours.
This page is editorial information, not medical advice. Compounded GLP-1 medications are not FDA-approved finished drug products, and GLP-1 medicines are not appropriate during pregnancy or while trying to conceive. On breastfeeding, injectable semaglutide labels describe missing milk data, while tirzepatide labels include a milk-transfer study with no infant-outcome data. Both require a discussion of breastfeeding benefits and clinical need; every GLP-1 pill label (Wegovy tablets, Rybelsus, Foundayo) says breastfeeding is not recommended. Talk to a licensed clinician about your history, hormones and goals — and your feeding plans — before starting any weight-management medication. See our affiliate disclosure and medical disclaimer.